Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
- DOI
- 10.1016/s1470-2045(26)00175-0
- Published
- 2026-09
- Container
- The Lancet Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00175-0,
title = {Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial},
author = {Zhengbo Song and Liming Zhu and Ying Liu and Rongbo Lin and Xingya Li and Yongzhong Luo and Yuan Yuan and Huaqiu Shi and Yiping Zhang and Baoyuan Zhang and Yinxin Zhu and Zaiqi Wang and Xiangdong Cheng},
year = {2026},
journal = {The Lancet Oncology},
doi = {10.1016/s1470-2045(26)00175-0},
url = {https://doi.org/10.1016/s1470-2045(26)00175-0}
}RIS
TY - JOUR TI - Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial AU - Zhengbo Song AU - Liming Zhu AU - Ying Liu AU - Rongbo Lin AU - Xingya Li AU - Yongzhong Luo AU - Yuan Yuan AU - Huaqiu Shi AU - Yiping Zhang AU - Baoyuan Zhang AU - Yinxin Zhu AU - Zaiqi Wang AU - Xiangdong Cheng PY - 2026 JO - The Lancet Oncology DO - 10.1016/s1470-2045(26)00175-0 UR - https://doi.org/10.1016/s1470-2045(26)00175-0 ER -
APA
Song, Z., Zhu, L., Liu, Y., Lin, R., Li, X., Luo, Y., Yuan, Y., Shi, H., Zhang, Y., Zhang, B., Zhu, Y., Wang, Z., & Cheng, X. (2026). Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00175-0
Source records
- crossref · retrieved 2026-09-26T00:38:08.166Z